uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Disease-modifying trials in Alzheimer's disease: a European task force consensus.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Geriatrics.
Show others and affiliations
2007 (English)In: Lancet Neurology, ISSN 1474-4422, E-ISSN 1474-4465, Vol. 6, no 1, 56-62 p.Article, review/survey (Refereed) Published
Abstract [en]

After symptomatic treatments, the new target for therapeutic approaches in Alzheimer's disease is the development of disease-modifying drugs. The concept of disease modification in Alzheimer's disease is controversial and the design of these trials raises many questions. Which populations should be studied? For how long? With which principal and secondary endpoints? Are surrogate markers available? Here, we present a European consensus on disease-modifying trials in Alzheimer's disease, agreed under the auspices of the European Alzheimer's Disease Consortium and based on the European perspective of the concept of disease modification, study designs, the role for biomarkers, risk benefit, and pharmacoeconomic issues.

Place, publisher, year, edition, pages
2007. Vol. 6, no 1, 56-62 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-144789DOI: 10.1016/S1474-4422(06)70677-9PubMedID: 17166802OAI: oai:DiVA.org:uu-144789DiVA: diva2:394434
Available from: 2011-02-02 Created: 2011-02-02 Last updated: 2011-10-07Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed
By organisation
In the same journal
Lancet Neurology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 171 hits
ReferencesLink to record
Permanent link

Direct link